CLINICAL TRIALS PROFILE FOR PENTOSAN POLYSULFATE SODIUM
✉ Email this page to a colleague
All Clinical Trials for Pentosan Polysulfate Sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003825 ↗ | Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-06-01 | RATIONALE: Pentosan polysulfate may be effective in treating side effects of radiation therapy to the abdomen or pelvis. It is not yet known whether pentosan polysulfate is more effective than no further therapy for treating gastrointestinal disturbance caused by previous radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of pentosan polysulfate in treating patients who have inflammation of the rectum, diarrhea, or blood in stools caused by previous radiation therapy to the abdomen and pelvis. |
| NCT00003825 ↗ | Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy | Completed | Radiation Therapy Oncology Group | Phase 3 | 1999-06-01 | RATIONALE: Pentosan polysulfate may be effective in treating side effects of radiation therapy to the abdomen or pelvis. It is not yet known whether pentosan polysulfate is more effective than no further therapy for treating gastrointestinal disturbance caused by previous radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of pentosan polysulfate in treating patients who have inflammation of the rectum, diarrhea, or blood in stools caused by previous radiation therapy to the abdomen and pelvis. |
| NCT00086684 ↗ | Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | 2003-09-01 | The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis. |
| NCT00236990 ↗ | An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland | Completed | Alza Corporation, DE, USA | Phase 2 | 1969-12-31 | The purpose of this study is to evaluate the safety and effectiveness of ELMIRON® in the treatment of chronic non-bacterial inflammation of the prostate gland. |
| NCT00236990 ↗ | An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland | Completed | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Phase 2 | 1969-12-31 | The purpose of this study is to evaluate the safety and effectiveness of ELMIRON® in the treatment of chronic non-bacterial inflammation of the prostate gland. |
| NCT00823030 ↗ | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Withdrawn | Northwell Health | N/A | 2009-01-01 | The purpose of this study is to determine the amount of improvement in bladder function and pain relief with the administration of 2% alkalinized lidocaine in patients with interstitial cystitis. Specifically, we want to see if the administration of 2% alkalinized lidocaine treatments in the bladder improves urodynamic test result values. We hope to enroll approximately 40 patients in this study. Previous research has shown that the administration of 2% alkalinized lidocaine in the bladder may improve the bladder's capacity to hold urine and urine flow rates while simultaneously providing pain relief. As part of standard of care at the Smith Institute of Urology Pelvic Pain Center, we routinely offer our IC patients 2% alkalinized lidocaine with follow up urodynamic evaluation. Our research looks to expand upon the prior studies and confirm the findings of improved bladder function and enhanced pain control of 2% alkalinized lidocaine versus placebo by performing a second urodynamic evaluation, which is not routinely performed. |
| NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pentosan Polysulfate Sodium
Condition Name
Clinical Trial Locations for Pentosan Polysulfate Sodium
Trials by Country
Clinical Trial Progress for Pentosan Polysulfate Sodium
Clinical Trial Phase
Clinical Trial Sponsors for Pentosan Polysulfate Sodium
Sponsor Name
| Sponsor Name for Pentosan Polysulfate Sodium | |
| Sponsor | Trials |
| Paradigm Biopharmaceuticals USA (INC) | 2 |
| McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | 1 |
| Northwell Health | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
